Abemaciclib

128 interactions 114 explained in plain English 328 cited references

Also sold as: Verzenio Verzenio®

About Abemaciclib

Abemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-po… Read the full Abemaciclib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 11, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mumps Virus Vaccine, Live Rubella Virus Vaccine, Live Smallpox Monkeypox Vaccine Typhoid Vaccine Varicella Virus Vaccine, Live Yellow Fever Vaccine

12 Contraindicated 75 Major 41 Moderate

All (128) Contraindicated (12) Major (75) Moderate (41)

Major

Abemaciclib Adagrasib Krazati Explained Increased CYP3A4 substrate exposure Details Abemaciclib Adenovirus Vaccine Type 4, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Adenovirus Vaccine Type 7, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Apalutamide Erleada Explained Reduced CYP3A4 substrate exposure Details Abemaciclib Asciminib Scemblix Explained Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Abemaciclib Avacopan Tavneos Explained Increased exposure to CYP3A4 substrate Details Abemaciclib Belzutifan Welireg Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Abemaciclib Berotralstat Orladeyo Explained Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Abemaciclib Carbamazepine Carbatrol Explained Decreased abemaciclib plasma concentration Details Abemaciclib Ceritinib Zykadia Explained Increased exposure of CYP3A substrate Details Abemaciclib Cholera Vaccine Ipol Explained An increased risk of infection by the live vaccine Details Abemaciclib Clomipramine Anafranil Explained Increased clomiPRAMINE exposure Details Abemaciclib Dabrafenib Tafinlar Explained Reduced sensitive CYP3A4 substrate exposure Details Abemaciclib Daridorexant Explained Increased CYP3A4 substrate with NTI exposure Details Abemaciclib Ebola Zaire Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Elinzanetant Lynkuet Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Abemaciclib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Enzalutamide Xtandi Explained Decreased abemaciclib plasma concentration Details Abemaciclib Fedratinib Inrebic Explained Increased CYP3A4 substrate exposure Details Abemaciclib Fexinidazole Explained An increased CYP3A4 substrate exposure Details Abemaciclib Fosphenytoin Cerebyx Explained Decreased abemaciclib plasma concentration Details Abemaciclib Gepotidacin Blujepa Explained Increased CYP3A4 substrate with NTI exposure Details Abemaciclib Givinostat Duvyzat Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Abemaciclib Influenza Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Ketoconazole Extina Explained Increased abemaciclib exposure Details Abemaciclib Lanreotide Explained Altered exposure to CYP3A4 substrate Details Abemaciclib Lazertinib Lazcluze Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Abemaciclib Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Abemaciclib Lenacapavir Sunlenca Explained Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Lonafarnib Zokinvy Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Abemaciclib Lumacaftor Explained Decreased abemaciclib plasma concentration Details Abemaciclib Mavorixafor Xolremdi Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Abemaciclib Metformin Fortamet® Increased metFORMIN exposure and an increased risk of lactic acidosis Details Abemaciclib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Abemaciclib Mitotane Lysodren Explained Decreased abemaciclib plasma concentration Details Abemaciclib Mobocertinib Exkivity Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Abemaciclib Nirmatrelvir Explained Increased abemaciclib plasma concentration Details Abemaciclib Nirogacestat Ogsiveo Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Abemaciclib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.